CAS 109882-30-6

Bendamustine USP Related Compound A (Free Form)

CAS : 109882-30-6

Formule : C₁₆H₂₃N₃O₄

Couleur et forme : White To Off-White Solid

Masse moléculaire : 321.38

Ref: 4Z-B-4316

Bendamustine USP Related Compound A-d8 (Free Form)

CAS : 109882-30-6

Formule : C₁₆H₁₅D₈N₃O₄

Couleur et forme : White To Off-White Solid

Masse moléculaire : 329.43

Ref: 4Z-B-4350

Bendamustine USP Related Compound A-d4 (Free Form)

CAS : 109882-30-6

Formule : C₁₆H₁₉D₄N₃O₄

Masse moléculaire : 325.40

Ref: 4Z-B-4349

Bendamustine USP Related Compound A

CAS : 109882-30-6

Formule : C₁₆H₂₃N₃O₄

Masse moléculaire : 321.37

Ref: ST-EA-CP-B7001

Dihydroxy Bendamustine Sodium Salt

Produit contrôlé

CAS : 109882-30-6

Stability Hygroscopic
Applications Dihydroxy Bendamustine is an impurity of Bendamustine (B132500).
References Watson, E., et al.: J. Pharm. Sci., 74, 1283 (1985), Teichert, J., et al.: Cancer Chemother. Pharmacol., 59, 759 (2007),

Formule : C₁₆H₂₂N₃NaO₄

Couleur et forme : Neat

Masse moléculaire : 343.35

Ref: TR-D446565

Dihydroxy bendamustine sodium salt

CAS : 109882-30-6

Dihydroxy bendamustine sodium salt is a medicinal protein analog that has been shown to be effective in the treatment of various types of cancer. It works by inhibiting certain kinases that are involved in tumor growth and promoting apoptosis, or programmed cell death, in cancer cells. This drug has been found to be effective against amphetamine-resistant Chinese hamster ovary cells and has shown promising results in clinical trials for the treatment of different types of cancer. Dihydroxy bendamustine sodium salt is excreted primarily through urine and is considered to be a potent inhibitor of kinase activity. Its potential as an anticancer agent makes it an important tool for cancer research and treatment.

Formule : C₁₆H₂₃N₃O₄

Degré de pureté : Min. 95%

Masse moléculaire : 321.37 g/mol

Ref: 3D-JEA88230